TCGA-AO-A1KS-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.430
- PROTEIN_SECRETION+0.420
- E2F_TARGETS+0.360
- MYC_TARGETS_V1+0.280
- ANDROGEN_RESPONSE+0.270
- UV_RESPONSE_DN+0.260
- TGF_BETA_SIGNALING+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- SPERMATOGENESIS+0.150
- MITOTIC_SPINDLE+0.140
Top 10 suppressed
- MYOGENESIS-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- COAGULATION-0.400
- P53_PATHWAY-0.360
- HYPOXIA-0.340
- ANGIOGENESIS-0.310
- INTERFERON_ALPHA_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- APICAL_JUNCTION-0.290
- GLYCOLYSIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.912 |
| 2 | SRR3147744 | — | — | 0.880 |
| 3 | ERR2598089 | fetal | fetal | 0.869 |
| 4 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.854 |
| 5 | 680dcf75-8d74-45ca-b1d6-0ef7310e6473 | — | — | 0.853 |
| 6 | SRR3147748 | — | — | 0.851 |
| 7 | MDT-AP-3021 | Med | Medulloblastoma | 0.847 |
| 8 | MDT-AP-3311 | Med | Medulloblastoma | 0.844 |
| 9 | SRR12475120 | — | — | 0.839 |
| 10 | SJEPD031786_D2.RNA-Seq | EPN | Anaplastic EPN | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |